CN-122005436-A - PH-ROS double-response fullerol gel for improving intestinal microbiota and application thereof in colonitis

Abstract

The invention discloses a pH-ROS double-response fullerol gel for improving intestinal microbiota and application thereof in colonitis, and belongs to the technical field of biological pharmacy. The invention provides an application of pH-ROS double-response fullerol gel SA-DA/CMCS-FPBA@C 60 (OH) 12 in treating ulcerative colitis by regulating intestinal microbiota. The fullerol gel can treat colitis by promoting a substantial increase in bifidobacterium beneficial bacteria, thereby reducing other harmful bacteria and maintaining escherichia, enterococcus and faecalis probiotic levels. The composition has potential effect of maintaining microbial homeostasis on patients suffering from ulcerative colitis after administration, has the characteristics of low toxicity, high efficiency and the like, and has good drug development prospect.

Inventors

• TANG JIA
• GE PENGYU
• NIU WANTING
• HONG LIU
• JING CHAOYANG
• LI XINNING
• LI YUCHAN

Assignees

• 江南大学

Dates

Publication Date

20260512

Application Date

20260206

Claims (10)

1. 1. Use of a fullerol complex gel for the manufacture of a medicament for alleviating symptoms of ulcerative colitis, characterised in that the alleviating symptoms of ulcerative colitis comprises improving intestinal flora, modulating inflammatory factors and/or modulating catalase.
2. 2. The use according to claim 1, wherein the method for preparing the fullerol composite gel comprises: (1) Adding a fullerol aqueous solution into the CMCS-FPBA aqueous solution, and uniformly mixing; (2) Adding CaC l2 solution until no new gel is generated, taking out the collected gel, vacuum freeze drying, grinding and pulverizing to obtain CMCS-FPBA@C 60 (OH) 12 microgel; (3) Adding SA-DA aqueous solution into CMCS-FPBA@C 60 (OH) 12 microgel, stirring, standing and suction filtering to obtain the hydrogel SA-DA/CMCS-FPBA@C 60 (OH) 12 .
3. 3. The use of claim 1, wherein said improving the intestinal flora comprises modulating the abundance of Pseudomonadota、Thermodesulfobacteriota、Lactobacillus、Actinobacteriota、Bifidobacerium、Verrucomicrobiota、Akkermansia.
4. 4. The use of claim 1, wherein the subject of the medicament is a mammal.
5. 5. The use of claim 4, wherein the subject is selected from the group consisting of a mouse, rat, rabbit, monkey, and human.
6. 6. The use according to claim 5, wherein the medicament is administered at a dose of not less than 0.4 mg/kg.
7. 7. The use according to claim 6, wherein the medicament further comprises a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable adjuvant.
8. 8. The use according to claim 7, wherein the pharmaceutically acceptable carrier comprises one or more of fillers, binders, wetting agents, disintegrants, lubricants, flavouring agents commonly used in medicine.
9. 9. The use according to claim 7, wherein the medicament is an oral dosage form.
10. 10. The use of the fullerol composite gel as claimed in claim 1 for the preparation of a health product for regulating intestinal flora.

Description

PH-ROS double-response fullerol gel for improving intestinal microbiota and application thereof in colonitis Technical Field The invention relates to a pH-ROS double-response fullerol gel for improving intestinal microbiota and application thereof in colonitis, and belongs to the technical field of biological pharmacy. Background Ulcerative colitis is a type of inflammatory bowel disease (Inflammatory Bowel Disease, IBD) characterized mainly by chronic inflammation and tissue damage of the colonic mucosa, and its global incidence has been on a continuous rise in recent years. The ulcerative colitis has long duration and easy recurrence, and brings long-term life quality reduction and remarkable social and economic burden to patients. Existing studies indicate that an imbalance of intestinal microbiota is one of the important contributors to the occurrence and progression of ulcerative colitis, and that abnormal changes in the structure of the intestinal microbiota can disrupt intestinal barrier function, induce immune disorders and exacerbate inflammatory responses. The current treatment for ulcerative colitis is mostly focused on inhibiting inflammatory reactions and relieving clinical symptoms, but the systemic regulation of intestinal microecological environment is still insufficient. Therefore, the functional material which can improve the structure of intestinal microbiota, simultaneously reduce inflammatory injury and restore intestinal homeostasis is developed, and has important significance for the intervention of ulcerative colitis and related intestinal diseases. Fullerene (C 60) is a zero-dimensional nanocarbon material with a unique electronic structure, has excellent Reactive Oxygen Species (ROS) scavenging ability, and has been applied to the study of various inflammation-related diseases. However, the existing fullerene derivatives are mostly applied in a short-term and large dosage to realize the antioxidation effect, and the attention on the aspects of intestinal microecology regulation and intestinal barrier repair is insufficient. Carboxymethyl chitosan (CMCS) and Sodium Alginate (SA) are natural polymer materials with good biocompatibility, wherein SA has adjustable swelling and gel characteristics under different pH conditions, and formylphenyl boric acid (FPBA) has high responsiveness to ROS, and is suitable for constructing a stimulus-responsive drug delivery system. Fullerol gels constructed based on the above materials, which are capable of modulating intestinal microbiota, have not been reported. Disclosure of Invention In view of the above, the present invention aims to provide a pH-ROS dual-response fullerene gel (SA-DA/CMCS-FPBA@C 60(OH)12) for improving the intestinal microbiota structure and realizing the intervention of the enteritis on the basis of the pH-ROS dual-response fullerene gel. In the present invention, female ICR mice were selected as model experimental animals for ulcerative colitis, and inflammatory models of ulcerative colitis were made by administration of sodium dextran sulfate (DSS). We have found for the first time that the fullerol microgel is effective in modulating intestinal flora to achieve the effect of treating ulcerative colitis. The invention provides application of a fullerene alcohol composite gel in preparing a medicament for relieving ulcerative colitis symptoms, wherein the relieving of ulcerative colitis symptoms comprises improving intestinal flora, regulating inflammatory factors and/or regulating catalase. In one embodiment, the preparation method of the fullerol composite gel comprises the following steps: (1) Adding a fullerol aqueous solution into the CMCS-FPBA aqueous solution, and uniformly mixing; (2) Adding CaC l2 solution until no new gel is generated, taking out the collected gel, vacuum freeze drying, grinding and pulverizing to obtain CMCS-FPBA@C 60(OH)12 microgel; (3) Adding SA-DA aqueous solution into CMCS-FPBA@C 60(OH)12 microgel, stirring, standing and suction filtering to obtain the hydrogel SA-DA/CMCS-FPBA@C 60(OH)12. In one embodiment, the improving the intestinal flora comprises modulating the abundance of Pseudomonadota、Thermodesulfobacteriota、Lactobacillus、Actinobacteriota、Bifidobacerium、Verrucomicrobiota、Akkermansia. In one embodiment, the subject of the medicament is a mammal, and the preferred subject is a rat, mouse, rabbit, monkey, or human. The material for treating ulcerative colitis is an oral preparation. The dosage of the present invention for the treatment of ulcerative colitis can be adjusted according to the subject. SA-DA/CMCS-FPBA@C 60(OH)12 is preferably used at a dose of 0.4 mg/kg. In one embodiment, the medicament further comprises a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable adjuvant. In one embodiment, the pharmaceutically acceptable carrier comprises one or more of fillers, binders, wetting agents, disintegrants, lubricants, flavoring agents commonly used in medicine.